TFF Pharmaceuticals Inc. (TFFP) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
2600 VIA FORTUNA, SUITE 360 AUSTIN, TX 78746 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 5,478 | 16,612 | 33,795 | 35,301 | 28,095 | |||
| Cash and cash equivalent | 5,478 | 16,612 | 33,795 | 35,301 | 28,095 | |||
| Other undisclosed current assets | 2,112 | 2,413 | 5,043 | 2,258 | 1,092 | |||
| Total current assets: | 7,590 | 19,025 | 38,838 | 37,559 | 29,187 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 120 | 196 | ||||||
| Property, plant and equipment | 2,000 | 3,078 | 1,860 | 1,103 | ||||
| Long-term investments and receivables | ||||||||
| Long-term investments | ||||||||
| Other noncurrent assets | 8 | 8 | ||||||
| Other undisclosed noncurrent assets | 2,310 | 1,813 | ||||||
| Total noncurrent assets: | 4,437 | 5,095 | 1,860 | 1,103 | ||||
| TOTAL ASSETS: | 12,027 | 24,120 | 40,698 | 38,662 | 29,187 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 2,244 | 920 | 1,494 | 1,298 | 411 | |||
| Accounts payable | 958 | 920 | 1,494 | 1,298 | 411 | |||
| Accrued liabilities | 1,286 | |||||||
| Deferred revenue | 101 | |||||||
| Other liabilities | 126 | 50 | 24 | |||||
| Other undisclosed current liabilities | 84 | 85 | ||||||
| Total current liabilities: | 2,429 | 1,131 | 1,544 | 1,322 | 411 | |||
| Noncurrent Liabilities | ||||||||
| Liabilities, other than long-term debt | 32 | 110 | ||||||
| Operating lease, liability | 32 | 110 | ||||||
| Other undisclosed noncurrent liabilities | 1,132 | |||||||
| Total noncurrent liabilities: | 32 | 110 | 1,132 | |||||
| Other undisclosed liabilities | 417 | |||||||
| Total liabilities: | 2,460 | 1,241 | 1,961 | 1,322 | 1,543 | |||
| Equity | ||||||||
| Equity, attributable to parent | 9,567 | 22,879 | 38,737 | 37,340 | 27,645 | |||
| Common stock | 2 | 36 | 25 | 23 | 18 | |||
| Additional paid in capital | 128,045 | 120,071 | 104,079 | 71,648 | 43,339 | |||
| Accumulated other comprehensive loss | (148) | (139) | (49) | (52) | ||||
| Accumulated deficit | (118,332) | (97,088) | (65,318) | (34,280) | (15,712) | |||
| Total equity: | 9,567 | 22,879 | 38,737 | 37,340 | 27,645 | |||
| TOTAL LIABILITIES AND EQUITY: | 12,027 | 24,120 | 40,698 | 38,662 | 29,187 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 734 | 496 | 88 | ||||
| Other income | 1,000,000 | 697 | |||||
| Cost of revenue (Cost of Product and Service Sold) | (747) | ||||||
| Gross profit: | (13) | 496 | 88 | ||||
| Operating expenses | (22,629) | (32,293) | (31,875) | (18,694) | (11,988) | ||
| Other undisclosed operating income | 747 | ||||||
| Operating loss: | (21,895) | (31,797) | (31,787) | (18,694) | (11,988) | ||
| Nonoperating income | 651 | 27 | 748 | 126 | 117 | ||
| Investment income, nonoperating | 266 | ||||||
| Debt instrument, convertible, beneficial conversion feature | 23,930 | 23,930 | |||||
| Interest and debt expense | (14) | ||||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||||
| Loss from continuing operations: | (21,258) | (31,770) | (31,039) | (18,567) | (11,870) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (31,039) | (18,567) | (11,870) | |
| Net loss: | (21,258) | (31,770) | (31,039) | (18,567) | (11,870) | ||
| Net income attributable to noncontrolling interest | 31,770 | 31,039 | |||||
| Other undisclosed net income (loss) attributable to parent | 14 | (31,770) | (31,039) | ||||
| Net loss attributable to parent: | (21,243) | (31,770) | (31,039) | (18,567) | (11,870) | ||
| Preferred stock dividends and other adjustments | (24,805) | ||||||
| Net loss available to common stockholders, diluted: | (21,243) | (31,770) | (31,039) | (18,567) | (36,675) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (21,258) | (31,770) | (31,039) | (18,567) | (11,870) | ||
| Other comprehensive income (loss) | 31,860 | 31,036 | 18,619 | ||||
| Comprehensive income (loss): | (21,258) | 90 | (3) | 52 | (11,870) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 31,770 | 31,039 | |||||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 6 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (21,252) | 31,860 | 31,036 | 52 | (11,870) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.